Key Takeaways
- • Delix closed a $100 million Series C financing, led by a strategic pharmaceutical partner and the SV Health neurodegeneration fund, according to the publisher summary.
- • The proceeds are earmarked to advance zalsupindole, described as the first true neuroplastogen analog of psychedelics, into Phase II development.
- • The financing was described as oversubscribed and is also intended to fund broader pipeline advancement and expansion.
- • The round is a notable institutional validation of neuroplastogen-based approaches in neurodegenerative disease, led by a strategic pharma investor alongside a dedicated health-focused fund.
Summary
Delix Therapeutics, a Bedford, Massachusetts-based company, has closed an oversubscribed $100 million Series C financing, according to a Business Wire announcement. The round was led by a strategic pharmaceutical investor and SV Health's neurodegeneration fund, per the publisher summary.
The capital is designated to advance zalsupindole, which the company describes as the first true neuroplastogen analog of psychedelic compounds, into Phase II clinical development. The company also cited broader pipeline advancement and expansion as uses of the proceeds.
The primary source available for this story was limited to the publisher summary, and the full article could not be retrieved, so specific details on trial design, indications, valuation, or existing investors beyond the lead participants are not available in this summary. Readers seeking clinical program specifics or the full terms of the round should refer to the original company announcement.
The capital is designated to advance zalsupindole, which the company describes as the first true neuroplastogen analog of psychedelic compounds, into Phase II clinical development. The company also cited broader pipeline advancement and expansion as uses of the proceeds.
The primary source available for this story was limited to the publisher summary, and the full article could not be retrieved, so specific details on trial design, indications, valuation, or existing investors beyond the lead participants are not available in this summary. Readers seeking clinical program specifics or the full terms of the round should refer to the original company announcement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.